.Discovery Park has named the successful applicants that will take part in its first ever Reactor programme, designed to supercharge life sciences firms’ potential to scale. Read more - ukspa.org.uk #DPReactor #ukspa #science #innovation #lifesciences #scienceparks

We're delighted to announce the ten companies that have successfully made it on to our Reactor programme! #DiscoverAmbition #DiscoverGrowth #DiscoveryPark #DPReactor kentonline.co.uk/kent-business/…

Great start to #Genesis21 physical- great job #MikeWard @DiscoveryPark_

Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing go.nature.com/3EIt47c

Researchers have developed a new version of prime editing that can install or swap out gene-sized DNA sequences in human cells — and could be a safer approach to gene therapy. broad.io/twin-prime-edi…

David R. Liu liugroup Broad Institute Harvard Chemistry @HHMINEWS Xin "Daniel" Gao New prime editing system inserts entire genes in human cells #NBTintheNews via Broad Institute broadinstitute.org/news/new-prime…

Future tech: - Artificial intelligence because we can’t convince people to use their natural one - EVs because we can’t convince people to ride bikes - Meat replacements because we can’t convince people to eat tofu - Virtual worlds because we’ve made the real one intolerable.

Wow. “4 genes were knocked out…including one that encodes a molecule that causes an aggressive human rejection response. A growth gene was also inactivated to prevent the pig’s heart from continuing to grow…6 human genes were inserted…to make the porcine organs more tolerable”

Researchers have developed a way to get #GeneEditing proteins inside cells in animal models with high enough efficiency to show therapeutic benefit. broad.io/gene-editing-0…

Cancer powerhouse AstraZeneca rolls the dice on a $75M cash bet on a buzzy upstart in the oncology field $AZN endpts.com/cancer-powerho…

"The Reactor Programme and being at Discovery Park in the Life Sciences Opportunity zone, allowed me to become a member of a larger life sciences community where collaboration is key." - Dr Vineeta Tripathi, Chief Executive & CSO, Vitarka Therapeutics🧪 bioindustry.org/news-listing/g…

Meet Darren Pitt, Chief Scientific Officer & Co-Founder of #VisusNano. Since joining Discovery Park in September 2020, VisusNano has received additional Innovate UK funding to fuel their growth 🧑‍🔬 Read their story here: visusnano.com #DiscoveryParkStories #VisusNano

Did you know that over 80% of our companies at Discovery Park collaborate together? 🤝 Occupying lab or office at Discovery Park means being part of a collaborative community of over 160+ companies. Find out more at discovery-park.co.uk. #DiscoveryParkPeople #Collaboration

Hear Dr Darren Pitt, VisusNano, explain how science & technology companies may no longer need to be located within the golden triangle, with Discovery Park being the same distance from London as Oxford or Cambridge 🔬🌎 #DiscoveryPark #VisusNano #BioTrinity #BioTrinity22 #Tech

Every day I pinch myself for having the opportunity to work with such talented and hard-working undergraduates, graduate students, postdocs, and collaborators. I’m grateful to National Academy of Sciences for recognizing their creativity and tireless determination.🙏

'The initial £1m from private funding will invest in exciting early-stage companies at start-up or to help them leverage funding without giving up equity or ownership' via @TheBusinessMag businessmag.co.uk/news/launch-of…

insidermedia.com/news/south-eas…

It was an honor to present how our students including Komor Lab, Nicole M. Gaudelli, and Andrew Anzalone developed base editing and prime editing, precision gene correction technologies, at the #LifeItself conference, hosted by Dr. Sanjay Gupta & Marc Hodosh.🙏 cnn.com/videos/health/…

The first human patients have been treated with base edited cells in an academic clinical trial in the UK led by Professor Waseem Qasim UCL. Allogeneic CAR-T cells containing multiple base edits are infused to treat relapsed or refractory T-cell leukemia. isrctn.com/ISRCTN15323014

Interview with the Broad Institute's David Liu: Is this the year base editing makes its mark? By Zach Brennan endpts.com/interview-with…